Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies cabozantinib to see how well it works compared with
placebo in treating patients with neuroendocrine or carcinoid tumors that have spread to
other places in the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine
kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may
slow tumor growth.